Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Hematology | Internal Medicine | Oncology | Conference News

Back to Journal Articles

ASH: Second-Line Drugs Target Chronic Myeloid Leukemia

Last Updated: December 08, 2009.

 

Almost all patients on nilotinib or dasatinib quickly achieve a complete cytogenetic response

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
In patients with drug-resistant chronic myeloid leukemia, two second-line drugs -- nilotinib and dasatinib -- may be at least as effective as the front-line drug imatinib, according to research presented this week at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.

TUESDAY, Dec. 8 (HealthDay News) -- In patients with drug-resistant chronic myeloid leukemia, two second-line drugs -- nilotinib and dasatinib -- may be at least as effective as the front-line drug imatinib, according to research presented this week at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.

In two separate trials, Jorge Cortes, M.D., of the M.D. Anderson Cancer Center in Houston, and colleagues studied the effects of 400 mg twice daily nilotinib in 65 patients, and the effects of either 50 mg twice daily or 100 mg once daily dasatinib in 62 patients, comparing the results with the historical record of imatinib.

After six months, the researchers found that a complete cytogenetic response was achieved by 96 percent of evaluable patients in the nilotinib trial and 94 percent of those in the dasatinib trial, significantly higher than response rates observed for 400 or 800 mg daily of imatinib (54 and 85 percent, respectively). In patients observed for up to 30 months, they found that both drugs were associated with a complete cytogenetic response rate similar to that of higher-dose imatinib.

"More patients taking nilotinib or dasatinib are achieving complete responses more quickly than they do on either of two daily doses of imatinib," Cortes said in a statement.

The studies were supported by Novartis and Bristol-Myers Squibb; several authors reported financial relationships with both companies.

Abstract - Nilotinib
Abstract - Dasatinib
More Information

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: ASH: Novel Drug Beneficial in Multiple Myeloma Next: Medroxyprogesterone Found Helpful in Prostate Cancer

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.